Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8
Animals
CD4-Positive T-Lymphocytes
/ virology
CD8-Positive T-Lymphocytes
/ immunology
HIV Infections
/ immunology
Humans
Interleukin-15
/ agonists
Lymphocyte Depletion
Macaca mulatta
Mice
Simian Acquired Immunodeficiency Syndrome
/ immunology
Simian Immunodeficiency Virus
/ physiology
Virus Latency
Virus Replication
/ immunology
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
12
03
2019
accepted:
12
12
2019
pubmed:
24
1
2020
medline:
22
4
2020
entrez:
24
1
2020
Statut:
ppublish
Résumé
Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that contain replication-competent virus
Identifiants
pubmed: 31969705
doi: 10.1038/s41586-020-1946-0
pii: 10.1038/s41586-020-1946-0
pmc: PMC7580846
mid: NIHMS1592991
doi:
Substances chimiques
Interleukin-15
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-159Subventions
Organisme : NIMH NIH HHS
ID : R01 MH108179
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126619
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143414
Pays : United States
Organisme : NIH HHS
ID : S10 OD025002
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125064
Pays : United States
Organisme : NIH HHS
ID : S10 OD026799
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111899
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIH HHS
ID : U42 OD011023
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123010
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI090797
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124436
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Références
Chun, T.-W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193–13197 (1997).
doi: 10.1073/pnas.94.24.13193
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
doi: 10.1126/science.278.5341.1295
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
doi: 10.1126/science.278.5341.1291
Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4
doi: 10.1038/nm880
UNAIDS. UNAIDS Data 2017. (2017).
The International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607–614 (2012).
doi: 10.1038/nri3262
Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
doi: 10.1038/nature11286
Archin, N. M. et al. HIV-1 expression within resting CD4
doi: 10.1093/infdis/jiu155
Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).
doi: 10.1016/S2352-3018(14)70014-1
Søgaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
doi: 10.1371/journal.ppat.1005142
Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
doi: 10.1371/journal.ppat.1004473
Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520–e529 (2015).
doi: 10.1016/S2352-3018(15)00226-X
Lim, S.-Y. et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci. Transl. Med. 10, eaao4521 (2018).
doi: 10.1126/scitranslmed.aao4521
Del Prete, G. Q. et al. TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia. JCI Insight 4, e127717 (2019).
doi: 10.1172/jci.insight.127717
Bekerman, E. et al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob. Agents Chemother. 63, e01163-19 (2019).
doi: 10.1128/AAC.01163-19
Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).
doi: 10.1038/s41586-018-0600-6
Nixon, C. C., Mavigner, M., Silvestri, G. & Garcia, J. V. In vivo models of human immunodeficiency virus persistence and cure strategies. J. Infect. Dis. 215, S142–S151 (2017).
doi: 10.1093/infdis/jiw637
Cartwright, E. K. et al. CD8
doi: 10.1016/j.immuni.2016.08.018
Xu, W. et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73, 3075–3086 (2013).
doi: 10.1158/0008-5472.CAN-12-2357
Han, K. P. et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–810 (2011).
doi: 10.1016/j.cyto.2011.09.028
Rhode, P. R. et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4, 49–60 (2016).
doi: 10.1158/2326-6066.CIR-15-0093-T
Jones, R. B. et al. A subset of latency-reversing agents expose HIV-infected resting CD4
doi: 10.1371/journal.ppat.1005545
Hofmann-Lehmann, R. et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses 16, 1247–1257 (2010).
doi: 10.1089/08892220050117014
Del Prete, G. Q. et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob. Agents Chemother. 58, 6790–6806 (2014).
doi: 10.1128/AAC.03746-14
Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
doi: 10.1038/nature12519
Li, H. et al. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl Acad. Sci. USA 113, E3413–E3422 (2016).
doi: 10.1073/pnas.1606636113
Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627–1632 (1999).
doi: 10.1001/jama.282.17.1627
Maldarelli, F. et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3, e46 (2007).
doi: 10.1371/journal.ppat.0030046
Chun, T. W. et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 204, 135–138 (2011).
doi: 10.1093/infdis/jir208
Chowdhury, A. et al. Differential impact of in vivo CD8
doi: 10.1128/JVI.00869-15
Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).
doi: 10.1093/cid/cit813
Kulpa, D. A. et al. Differentiation to an effector memory phenotype potentiates HIV-l latency reversal in CD4
doi: 10.1128/JVI.00969-19
Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430–1440 (2018).
doi: 10.1038/s41591-018-0130-7
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
doi: 10.1093/oxfordjournals.aje.a118408
Chahroudi, A. et al. Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog. 10, e1003958 (2014).
doi: 10.1371/journal.ppat.1003958
Kumar, N. A. et al. Antibody-mediated CD4 depletion induces homeostatic CD4
pubmed: 30185596
pmcid: 6206490
Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog. Immun. 1, 68–106 (2016).
doi: 10.20411/pai.v1i1.100
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
doi: 10.1093/bioinformatics/btr260
Smith, S. A. et al. Diversification in the HIV-1 envelope hyper-variable domains V2, V4, and V5 and higher probability of transmitted/founder envelope glycosylation favor the development of heterologous neutralization breadth. PLoS Pathog. 12, e1005989 (2016).
doi: 10.1371/journal.ppat.1005989
Smith, S. A. et al. Signatures in simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques. J. Virol. 90, 1880–1887 (2016).
doi: 10.1128/JVI.02711-15
Burton, S. L. et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc. Natl Acad. Sci. USA 112, 10780–10785 (2015).
doi: 10.1073/pnas.1509731112
Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Medicine 5, e16 (2008).
Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2011).
Denton, P. W. et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85, 7582–7593 (2011).
Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316–1322 (2006).
Honeycutt, J. B. et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J. Clin. Invest. 128, 2862–2876 (2018).
Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep. 21, 600–611 (2017).
Tsai, P. et al. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology 13, 36 (2016).